Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02067039 · ClinicalTrials.gov registry record · NA
Evaluation of Rapid HIV Self-testing Among MSM (eSTAMP)
A NA study, sponsored by Centers for Disease Control and Prevention.
- Completed
- Registry status
- NA
- Development phase
- 2,665
- Enrollment target
NCT02067039: Completed NA study, sponsored by Centers for Disease Control and Prevention.
NCT02067039 is a NA study that has completed, run by Centers for Disease Control and Prevention. The registered enrollment target is 2,665 participants, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02067039, a NA study, has completed, sponsored by Centers for Disease Control and Prevention.
- COMPLETED
- Registry status
- NA
- Development phase
- 2,665 participants
- Enrollment target
Study Summary
This study seeks to determine the public health impact of providing rapid HIV test kits to men who have sex with men (MSM) so they may test themselves at their convenience. The study will determine if men who receive the rapid HIV test kits report HIV testing at least three times per year. This study will be conducted in four consecutive parts. The first three parts are formative in nature to guide the development and implementation of Part 4 of the study. The research study will use two different types of rapid HIV tests. The OraQuick® In-Home HIV Test for oral fluid (FDA approved for home use) and Sure Check® HIV 1/2 Assay, currently FDA-approved for professional use and distributed in the U.S. as Clearview® Complete HIV-1/2 Rapid Test. An Investigational Device Exemption will be obtained from the FDA to allow the contractor to supply the Sure Check® HIV 1/2 Assay to study participants since it is not approved for home use.
Primary Outcome
Frequency of HIV testing \>=3 times reported by participants over a 12-month follow-up period.
Interventions
- DEVICE OraQuick in home & Sure Check HIV tests
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,665 participants |
| Start Date | 2015-03-25 |
| Est. Completion | 2016-10-21 |
| Phase | NA |
What the finished NCT02067039 record still lists
NCT02067039 is an interventional study that assigns participants to a tested intervention. Its 2,665 participants enrollment target places it among the larger protocols in the corpus, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% higher).
The record links to 0 conditions, and to 1 intervention - of which OraQuick in home & Sure Check HIV tests is the first listed.
NCT02067039 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02067039 about?
NCT02067039 is a clinical study titled "Evaluation of Rapid HIV Self-testing Among MSM (eSTAMP)". This study seeks to determine the public health impact of providing rapid HIV test kits to men who have sex with men (MSM) so they may test themselves at their convenience. The study will determine if men who receive the rapid HIV test kits report HIV testing at least three times per year. This stud...
What is the current status of trial NCT02067039?
This trial is currently completed. It is a NA study. The enrollment target is 2,665 participants. The study started on 2015-03-25. Estimated completion is 2016-10-21.
What interventions are being tested in trial NCT02067039?
The interventions under investigation include: OraQuick in home & Sure Check HIV tests (DEVICE).
Who is sponsoring clinical trial NCT02067039?
This trial is sponsored by Centers for Disease Control and Prevention, which has 139 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02067039's enrollment target sits among peer trials
2,665 44th of 2000 higher than 1,957 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05471908 · 2,674 participants · NA
Follow-up Automatically vs. As-Needed Comparison (FAAN-C) Trial
- NCT06825715 · 2,653 participants · NA
Multilevel Intervention for Precision Oncology
- NCT05111925 · 2,690 participants
Pre- and Post-neuromusculoskeletal Injury Risk Evaluation for Return-to-Duty Enhancement
- NCT06455085 · 2,634 participants · NA
RESTORE: REducing Future fractureS and Improving ouTcOmes of fRagility fracturE
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI